PlainPharmaWatch

CMS Open Payments · Program Year 2024

Blue Sky Bio, LLC

Blue Sky Bio, LLC reported $8,658,422.00 across General Payments, Research, and Ownership to 48 physicians and teaching hospitals across 50 transactions.

$8.7M Top 10% payer
All-tracks total
50 Below-median volume
Transactions
48 Below-median reach
Recipients
+$31.8K
General Payments vs PY2023

Blue Sky Bio, LLC reported $8,658,422.00 across all CMS Open Payments tracks (General + Research + Ownership) to 48 physicians and teaching hospitals in Program Year 2024 - ranking #193 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $314,197.00, averaging $180.4K per recipient.

How Blue Sky Bio, LLC's $8.7M all-tracks total breaks down

Blue Sky Bio, LLC's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

30/100

Total payments

A

90/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

10/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer blue-sky-bio-llc Blue Sky Bio, LLC

$8.7M · #193/1,925 · 0.1% industry · PY2024

  • TOT $8.7M
  • RANK #193
  • SHARE 0.1%
  • TXN 50
  • RCP 48
  • CAT 1
  • GEN $314.2K
  • ΔGEN +$31.8K
  • TOP1 38.2%
  • PY 2024

Nearest volume peer: Contego Medical, Inc ($8.7M)

SpectraWAVE, Inc$8.7MBlue Sky Bio, LLC (this)$8.7MContego Medical, Inc$8.7MSi-Technology, LLC$8.6MIgnite Orthopedics, LLC$8.6M
All-tracks payment totals near Blue Sky Bio, LLC (CMS Open Payments PY2024)

Blue Sky Bio, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Blue Sky Bio, LLC's CMS-reported General Payments increased by $31.8K (+11.3%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: BLUE SKY BIO, LLCPY2023: BLUE SKY BIO, LLCPY2024: Blue Sky Bio, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$282.4KPY2024$314.2K
PY2023
$282,400.00
PY2024
$314,197.00

What the Data Shows for Blue Sky Bio, LLC

The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Blue Sky Bio, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.

"Consulting Fee" leads the 1-category general-payment breakdown below at $314.2K (100.0% of General Payments, 48 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 1 types of general payments, Blue Sky Bio, LLC's largest category was "Consulting Fee" at $314.2K - 100.0% of General Payments.

How Blue Sky Bio, LLC divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$314.2K
Payment Type Amount Transactions
Consulting Fee $314.2K 48

Recipient Concentration in General Payments

The five largest recipient relationships account for $314,197.00 (100.0%) of $314,197.00 in this company's General Payments records across 4 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Blue Sky Bio, LLC

The five named recipients with the highest reported General Payments from this company

Nathan Cory Glenn$120.0KBaron Grutter$74.2KRobert Mikhli$60.0KMarc Lipkin$60.0K
  1. 1

    Nathan Cory Glenn

    $120,000.00 across 12 reported transactions

  2. 2

    Baron Grutter

    $74,197.00 across 12 reported transactions

  3. 3

    Robert Mikhli

    $60,000.00 across 12 reported transactions

  4. 4

    Marc Lipkin

    $60,000.00 across 12 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Blue Sky Bio, LLC ranks #193 of 1,925 by total payments (top 10% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #606 of 1,838 by HHI (top 33% most concentrated), a wider distribution than most similarly sized payers.

00.81.62.43.12730.32744.92759.52774.12788.7Total payments ($M)Concentration (HHI, 0-10,000)
Blue Sky Bio, LLC (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Blue Sky Bio, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Blue Sky Bio, LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Blue Sky Bio, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Blue Sky Bio, LLC ranks #193 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Blue Sky Bio, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.